Products

Vedro

Readable·Scalable·Pragmatic

vedro.io Source★ 6Apache-2.0 TelegramSoftware Development / Testing & Code Quality

AI Benchmark
Desktop
Mobile
Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
Free
No monthly subscription pricing
Creators
Nikita Tsvetkov
@vedro_universe· 4 followers
Launched
3y ago
2023-08-02 · Est.

Traffic

Monthly visitsData through Oct 2026

Marketing moves

Launches, search & content, referrals, promotions
X accounts@vedro_universe
  • Launched on Product HuntLaunch

    Pragmatic Testing Framework

    Aug 2, 2023 · 3y agoLaunch page

Open Source & Self-Hosting

GitHub · MCP / Skill
Last commit 2026-07-24
GitHub Stars
★ 6
Forks
1
License
Apache-2.0
Primary language
Python

Traffic sources

Oct 2026

Traffic breakdown

Channels

  • Direct41%
  • Organic Search33%
  • Referrals10%
  • Social7%
  • Other9%

Countries

  • Mexico100%

Search

Domain authority —Domain registered 2019-05-07

KeywordMonthly volume
what makes if statements hard380

Traffic data: Vaneform

Pricing

Pricing page not identified yet, or no public pricing listed.

Pages & changes

Tracked since 2023-08-02

Key pages

Weekly snapshots
vedro.io/ Snapshot 2026-11-04

Changes

No pricing, plan, or positioning changes detected since tracking started.

Questions & evidence

How much website traffic does Vedro get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is Vedro and what platforms does it support?
Vedro is catalogued under Testing & Code Quality: Readable·Scalable·Pragmatic. Supported platforms: Web.
Is Vedro open source?
Vedro has a public repository (https://github.com/vedro-universe/vedro) under the Apache-2.0 license, recording 6 GitHub stars.Source

Related products in this category

Software Development / Testing & Code Quality

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.